Claudio Dazzi
A5085427107- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroendocrine Tumor Research Advances
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Neutropenia and Cancer Infections
- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Intraperitoneal and Appendiceal Malignancies
- Hematopoietic Stem Cell Transplantation
- Appendicitis Diagnosis and Management
- Breast Cancer Treatment Studies
- Peptidase Inhibition and Analysis
Ospedale "Santa Maria delle Croci" di Ravenna
2001-2022
Azienda Unità Sanitaria Locale Della Romagna
2017-2021
AC Camargo Hospital
2018
Medica (Italy)
2018
Azienda Ospedaliero-Universitaria Careggi
2017
Ospedale Santa Maria
1997-2016
Istituto Oncologico Romagnolo
2006-2015
Humanitas University
2015
University of Bologna
2015
Ospedale Santa Maria della Misericordia di Rovigo
2015
Abstract Purpose: To analyze the impact of TP53 mutations on response to first-line tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC). Experimental Design: 136 NSCLC receiving TKIs were analyzed. evaluated 123 relation disease control rate (DCR), objective (ORR), progression-free survival (PFS), and overall (OS). Results: observed 37 (30.1%), 10 (27.0%), 6 (16.2%), 9 (24.3%), 12 (32.4%) exons 5, 6, 7, 8, respectively. DCR was 70% TP53-mutated...
MET-deregulated NSCLC represents an urgent clinical need because of unfavorable prognosis and lack specific therapies. Although recent studies have suggested a potential role for crizotinib in patients harboring MET amplification or exon 14 mutations, no conclusive data are currently available. This study aimed at investigating activity ROS1 alterations.Patients with pretreated advanced evidence rearrangements (cohort A) deregulation (amplification, ratio MET/CEP7 >2.2 cohort B) were treated...
Purpose Considering promising results in phase II studies, a randomized III trial was designed to assess the efficacy of adding bevacizumab first-line cisplatin plus etoposide for treatment extensive-disease (ED) small-cell lung cancer (SCLC). Patients and Methods Treatment-naive patients with ED-SCLC were randomly assigned receive either (arm A) or same regimen B) maximum six courses. In absence progression, arm B continued alone until disease progression 18 The primary end point overall...
Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available non-Asian patients. BEVERLY is an Italian, multicenter, randomized, phase 3 investigating addition as first-line treatment NSCLC.Eligible randomized 1:1 plus or alone. Investigator-assessed PFS and blinded independent centrally reviewed coprimary end points. With 80% power detecting a 0.60 hazard ratio two-sided...
Abstract Background As yet, no population-based prospective studies have been conducted to investigate the incidence and clinical outcome of glioblastoma (GBM) or diffusion impact current standard therapeutic approach in newly diagnosed patients younger than aged 70 years. Methods Data on all new cases primary brain tumors observed from January 1, 2009, December 31, 2010, adults residing within Emilia-Romagna region were recorded a registry Project Emilia Romagna Neuro-Oncology (PERNO)....
Purpose 64Cu-ATSM is a very promising PET radiopharmaceutical for tumor imaging of hypoxia. One the advantages this compound compared with other hypoxia-avid tracers high tumor-to-background signal offered, which guaranties facilitated delineation. This study analyzes optimal semiquantitative and quantitative parameters obtained by PET/CT in same cohort patients special focus on their correlation to disease outcome. Patients Methods A prospective recruitment 18 consecutive (M:F, 13:5; mean...
Tyrosine kinase inhibitors (TKIs) are very efficacious in non-small-cell lung cancer (NSCLC) patients harboring activating Epidermal Growth Factor Receptor (EGFR) mutations. However, about 10% of EGFR wild type (wt) respond to TKI, with unknown molecular mechanisms sensitivity. We considered a case series 34 wt NSCLC responsive erlotinib after at least one line therapy. Responsive were matched an equal number non-responsive patients. A panel 26 genes, for total 214 somatic mutations, was...
Abstract Background Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study designed evaluate and safety of nab-paclitaxel in relapsed SCLC. Methods multicentre prospective Phase 2 trial, refractory or sensitive SCLC progressed platinum-based chemotherapy received 100 mg/smq on days 1, 8, 15 every 4 weeks up six cycles,...
We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 μmlg/Kg, B) as a mobilizing regimen, could result in harvesting different numbers CD34+ cells, committed progenitors and cells subsets. The number considered target for each chemotherapy was ≥ 2 × 106/Kg/bw. Fifteen leukaphereses procedures were necessary A, while 16 performed B. did not observe any difference between two groups terms...